

# Bram Verstockt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9047590/bram-verstockt-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

2,351  
citations

22  
h-index

47  
g-index

183  
ext. papers

3,889  
ext. citations

4.1  
avg, IF

5.37  
L-index

#	Paper	IF	Citations
154	P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i423-i424	1.5	
153	P401 Tofacitinib tissue exposure correlates with endoscopic outcome. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i394-i395	1.5	0
152	P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i157-i158	1.5	
151	N18 Introduction of inflammatory bowel disease specialized dietitian and nutritional status in a multidisciplinary IBD team. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i624-i625	1.5	0
150	P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i136-i136	1.5	1
149	DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i131-i132	1.5	
148	Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2022</b> , 3, 100089	3	0
147	P591 Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i528-i529	1.5	
146	P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohn's disease: a new antifibrotic target?. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i182-i183	1.5	
145	P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i210-i210	1.5	
144	P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i177-i178	1.5	
143	DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i066-i067	1.5	
142	P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i424-i424	1.5	0
141	P475 Profiling the use of Complementary Alternative Medicines among IBD patients. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i445-i446	1.5	
140	DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn's Disease in the SERENE studies. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i124-i125	1.5	2
139	P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i151-i151	1.5	
138	DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i058-i058	1.5	

137	P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i460-i461	1.5	
136	OP30 Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i033-i034	1.5	0
135	DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLIBRI consortium. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i123-i124	1.5	0
134	P647 Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i561-i561	1.5	
133	P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i427-i428	1.5	
132	P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i298-i299	1.5	
131	Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression.. <i>iScience</i> , <b>2022</b> , 25, 103963	6.1	1
130	Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 885-886	6.1	1
129	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis.. <i>Nature Communications</i> , <b>2022</b> , 13, 2299	17.4	0
128	Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways.. <i>Npj Systems Biology and Applications</i> , <b>2022</b> , 8, 15	5	0
127	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 988-993	1.5	3
126	Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 754413	8.4	4
125	Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	1
124	How do we predict a patient's disease course and whether they will respond to specific treatments?. <i>Gastroenterology</i> , <b>2021</b> ,	13.3	2
123	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	2
122	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	19
121	S808 Mechanisms of Non-Response to Adalimumab on Inflammatory Bowel Disease: Peripheral Proteomic and Transcriptomic Profiling from the SERENE-CD and SERENE-UC Studies. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, S375-S376	0.7	
120	Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 870-886	4.5	4

119	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 879-913	1.5	22
118	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1443-1454	1.5	5
117	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3776-3789	3.8	0
116	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1407-1409	1.5	2
115	P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S168-S168	1.5	2
114	DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S061-S062	1.5	
113	P063 The immunological landscape of intestinal fibrosis in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S168-S169	1.5	
112	OP14 Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S014-S015	1.5	
111	P095 Initial disease course in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S192-S193	1.5	
110	Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 618856	5.7	7
109	P361 No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S380-S380	1.5	
108	P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S336-S337	1.5	
107	DOP08 Serum proteomics predict endoscopic remission in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S046-S047	1.5	
106	P465 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S456-S457	1.5	
105	P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S335-S336	1.5	
104	P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S142-S143	1.5	
103	DOP07 Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect key pathogenesis pathways and facilitate patient stratification. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S045-S046	1.5	
102	P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn's disease patients achieving endoscopic remission. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S338-S339	1.5	

101	DOP37 Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S075-S076	1.5	
100	OP09 Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S008-S009	1.5	0
99	ECCO Topical Review: Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1605-1620	1.5	7
98	Breaking the therapeutic ceiling in drug development in ulcerative colitis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 589-595	18.8	17
97	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	2
96	Point-of-Care Intestinal Ultrasound Examination: Prime Time for the Management of Ulcerative Colitis?. <i>Gastroenterology</i> , <b>2021</b> , 160, 964-965	13.3	0
95	Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 692-693	1.5	0
94	Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. <i>Gut</i> , <b>2021</b> , 70, 1416-1418	19.2	3
93	Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 485-498	1.5	16
92	Point-of-care intestinal ultrasonography in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 209-210	24.2	1
91	Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , <b>2021</b> , 9, 624416	3.4	1
90	Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1564-1575	4.5	11
89	Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ Receptor Signaling Pathways. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 627535	8.4	4
88	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1431-1442	1.5	7
87	Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohn's Disease, Dream or Reality?. <i>Gastroenterology</i> , <b>2021</b> , 161, 353-355	13.3	1
86	Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 1323-1327	2.4	0
85	Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER case series. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	1
84	Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. <i>Scientific Reports</i> , <b>2021</b> , 11, 18243	4.9	2

83	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1410-1430	1.5	11
82	Ex Vivo Mimicking of Inflammation in Organoids Derived From Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1564-1567	13.3	13
81	Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> ,	1.5	5
80	P061 The molecular landscape of perianal fistula in Crohn's disease: opportunities for new therapeutic approaches. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S165-S165	1.5	1
79	P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S502-S502	1.5	2
78	Big data in IBD: big progress for clinical practice. <i>Gut</i> , <b>2020</b> , 69, 1520-1532	19.2	40
77	Short- and Long-term Outcomes Following Side-to-side Strictureplasty and its Modification Over the Ileocaecal Valve for Extensive Crohn's Ileitis. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1378-1384	1.5	5
76	P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S369-S370	1.5	2
75	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 480-489	1.5	9
74	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 4-22	1.5	320
73	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 155-168	1.5	122
72	Personalised medicine in Crohn's disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 80-92	18.8	15
71	Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. <i>Current Opinion in Pharmacology</i> , <b>2020</b> , 55, 17-30	5.1	10
70	P145 Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S209-S210	1.5	
69	P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn's ileitis: single-centre long-term outcome. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S365-S366	1.5	
68	P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S411-S412	1.5	1
67	P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S531-S532	1.5	1
66	Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1847	8.4	13

65	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. <i>Cells</i> , <b>2020</b> , 9,	7.9	2
64	P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S462-S463	1.5	
63	Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2294-2297	4	4
62	Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 794-796	18.8	3
61	Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1142-1151.e10	6.9	22
60	Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 332-341	1.5	18
59	Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1488-1493	1.5	18
58	OP11 Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S007-S007	1.5	2
57	DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease : a multi-centre Belgian cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S044-S045	1.5	0
56	DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S047-S048	1.5	1
55	DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S048-S048	1.5	1
54	Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. <i>EBioMedicine</i> , <b>2019</b> , 40, 733-742	8.8	60
53	OP10 Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S006-S007	1.5	
52	DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S072-S073	1.5	6
51	P342 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S273-S274	1.5	3
50	Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 864-872	1.5	48
49	Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 572-581	6.1	28
48	New biologics and small molecules in inflammatory bowel disease: an update. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819853208	4.7	50

47	P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S533-S533	1.5	
46	P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S385-S385	1.5	
45	Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1401-1409	1.5	51
44	P011 Signalling and transcriptional network propagation uncovers novel ulcerative colitis pathogenetic pathways from single-nucleotide polymorphisms. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S091-S092	1.5	
43	P478 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S351-S351	1.5	
42	P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S537-S538	1.5	
41	Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 750-758	5.3	6
40	P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S300-S300	1.5	
39	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 144-164	1.5	427
38	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 273-284	1.5	132
37	TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. <i>Gut</i> , <b>2019</b> , 68, 1531-1533	19.2	30
36	P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S102-S102	1.5	
35	Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 943-954	6.4	22
34	DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S040-S040	1.5	2
33	Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological Materials. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 230	4.9	1
32	817 Identification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohn's Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S471-S471	0.7	
31	P836 The predictive role of gut microbiota in treatment response to vedolizumab and ustekinumab in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S542-S542	1.5	1
30	Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1215-1225	5.3	11



29	Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 668-673	2.2	5
28	Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1175-1181	4	17
27	Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 916-930	1.5	18
26	GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 389-394	1.5	17
25	Genome-wide association studies in Crohn's disease: Past, present and future. <i>Clinical and Translational Immunology</i> , <b>2018</b> , 7, e1001	6.8	45
24	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 402-407	1.5	48
23	New treatment options for inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 585-590	6.9	98
22	Ten-year survival after endoscopic stent placement as a bridge to surgery in obstructing colon cancer. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 87, 705-713.e2	5.2	27
21	Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 731-739	6.1	41
20	Genetic Influences on the Development of Fibrosis in Inflammatory Bowel Disease <b>2018</b> , 13-38		
19	P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn's disease and provide insights in the mechanism of action. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S110-S110	1.5	1
18	Effects of Epithelial IL-13R $\alpha$ Expression in Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2983	8.4	9
17	P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S113-S113	1.5	
16	DOP018 Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S041-S042	1.5	1
15	When IBD is not IBD. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 1085-1088	2.4	6
14	DOP003 Ustekinumab induces clinical and biological remission in biologic refractory Crohn's disease patients: A real-world Belgian cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S031-S032	1.5	
13	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2442-2451	4.5	42
12	Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1937-1946.e8	6.9	79

11	Estrogen receptor $\alpha$ controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 5798-5803	11.5	18
10	Genetics of inflammatory bowel disease: beyond NOD2. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 224-234	18.8	68
9	Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?. <i>Gut</i> , <b>2017</b> , 66, 2193-2195	19.2	23
8	A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 809-821	4.1	28
7	Increased Baseline TNF-Driven Pathways Observed in Patients with Crohn's Disease not Responding to Infliximab. <i>Gastroenterology</i> , <b>2017</b> , 152, S767	13.3	2
6	Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 31-47	5.4	20
5	P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, S96-S97	1.5	
4	An unusual cause of severe, persistent diarrhoea. <i>Acta Gastro-Enterologica Belgica</i> , <b>2017</b> , 80, 416-418	0.6	
3	Genetic Influences on the Development of Fibrosis in Crohn's Disease. <i>Frontiers in Medicine</i> , <b>2016</b> , 3, 24	4.9	16
2	A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 1120-6	1.5	37
1	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in a complex disease		2